← 產業報告目錄

Diabetes Care Devices Market by Product Type (Blood Glucose Monitoring (CGM), Insulin Delivery Devices (Insulin Pumps (Tethered), Insulin Pens, Pen Needles), Application) Disease Type (Type 1, Type 2), End User (Homecare/Self) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-09-16頁數 304報告編號 MD3684

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global diabetes care devices market is projected to reach 61.2 billion in 2030 from USD 34.3 billion in 2025, at a CAGR of 12.3% during the forecast period. The rising prevalence of diabetes, driven by sedentary lifestyles, obesity, and changes in dietary habits, is significantly increasing the demand for effective monitoring and management tools for diabetes care. The growing geriatric population, which is more susceptible to type 2 diabetes and its complications, further boosts the demand for glucose monitoring devices. Additionally, increased awareness and a greater focus on preventive healthcare are encouraging early diagnosis and self-management tools, which are enhancing the use of home-based devices. Technological advancements also make these devices more appealing to both patients and healthcare providers. Wider market adoption may be limited by the high cost of devices and, in certain markets, low consumer acceptance or adherence. By product type, the blood glucose monitoring segment is expected to account for the largest share of the global diabetes care devices market. The global diabetes care devices market is divided into three main segments: blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. The blood glucose monitoring system segment holds the largest market share due to its strong functional advantages and medical support. These devices provide accurate real-time tracking, which helps prevent complications. Rising diabetes prevalence, physician recommendations, and innovations like smartphone integration further increase home adoption settings. By patient care settings, the self/home healthcare segment is expected to account for the largest share of the global diabetes care devices market. The global diabetes care devices market is segmented by patient care settings into the following categories: self/home healthcare and hospitals & diabetes specialty clinics. Among these, the self/home healthcare segment is expected to hold the largest market share. The increasing demand for convenient, cost-effective devices is driving growth in this area. Many people rely on self-testing devices, such as continuous blood glucose monitors, which reduce the need for clinical visits. Rising awareness of preventive care, advancements in both portable and connected technologies, and an increasing geriatric population, which is more susceptible to type 2 diabetes, are fueling the growth in demand for self/homecare devices. By disease type, the type 2 diabetes segment is expected to account for the largest share of the global diabetes care devices market. This dominance is mainly driven by lifestyle-related risk factors such as sedentary behavior, dietary habits, and increasing obesity, which make type 2 diabetes more prevalent in the population. The rise in obesity, fueled by high-calorie diets, processed foods, and physical inactivity, is the primary contributor to its rapid growth. Urbanization and modernization have further reduced daily physical activity while increasing access to fast food, leading to rising rates across both developed and developing countries. The disease is also strongly age-related, with older adults being more susceptible, and as global populations age, the prevalence naturally continues to rise. The diabetes care devices market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The rapid rise in diabetes cases and the increasing demand for advanced diabetes care are driving a strong need for diabetes care devices in the Asia Pacific region. Additionally, global leaders in diabetes care products are expanding their footprint in the Asia Pacific by launching advanced formulations and digitally integrated diabetes care devices. A breakdown of the primary participants (supply side) for the diabetes care devices market referred to in this report is provided below: • By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%) • By Designation: C-level Executives (20%), Directors (35%), and Others (45%) • By Region: North America (30%), Europe (25%), Asia Pacific (20%), Latin America (20%), Middle East & Africa (2%), GCC Countries (3%) Prominent players in the diabetes care devices market include F. Hoffmann Roche Ltd (Switzerland), Abbott Laboratories (US), Medtronic (Ireland), Dexcom (US), Insulet Corporation (US), B Braun Se (Germany), Embecta Corp (US), Nipro (Japan), Senseonics (US), Ypsomed (Switzerland), i-Sens, Inc (South Korea), Tandem Diabetes Care, Inc (US), ACON LABORATORIES, INC (US), ARKRAY, INC(Japan), Terumo Corporation (Japan), Sinocare Inc (Japan), Waveform Diabetes (AgaMatrix) (US), Lifescan IP Holdings (US), SD Biosensor, Inc (South Korea), DeBiotech SA. (Switzerland), Sungshim Medical Co, Ltd (South Korea), Sooil Developments Co., Ltd (South Korea), Hindustan syringes and medical devices (India), Microgene Diagnostic Systems Pvt Ltd (India), Rossmax International Ltd (Taiwan) Research Coverage The report provides an analysis of the diabetes care devices market, focusing on estimating the market size and potential for future growth across various segments, including distribution channels, regions, indications, and product types. Additionally, the report features a competitive analysis of the key players in the market, detailing their company profiles, product and service offerings, recent developments, and key market insights strategies. Reasons to Buy the Report The report offers valuable insights for both market leaders and new entrants in the diabetes care devices industry, providing estimated revenue figures for the entire market and its subsegments. It helps stakeholders understand the competitive landscape, allowing them to better position their businesses and develop effective go-to-market strategies. Additionally, the report emphasizes key market drivers, restraints, challenges, and opportunities, assisting stakeholders in assessing the current state of the market. This report provides insights into the following pointers:  Analysis of key drivers (growing burden of diabetes care globally, rising geriatric population, increasing awareness and preventive healthcare focus, technological advancements), restraints (high cost of innovative diabetes devices, limited awareness in emerging markets), opportunities (enhanced diabetes management with advanced patient-implantable CGM devices) and challenges (limited sensor durability leading to repeated and costly replacements, high cost and socio-economic disparities in access to devices). • Market Penetration: This report provides detailed information on the product portfolios offered by major players in the global diabetes care devices market. It covers various segments, including product types, patient care settings, and regions. • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global diabetes care devices market. • Market Development: Thorough knowledge and analysis of the profitable rising markets by product types, patient care settings, disease type, and regions. • Market Diversification: Comprehensive information about newly launched products and services, expanding markets, current advancements, and investments in the global diabetes care devices market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global diabetes care devices market.
目錄 Table of Contents
1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 29 1.3 STUDY SCOPE 30 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 30 1.3.2 INCLUSIONS & EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 32 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 33 1.5 SUMMARY OF CHANGES 33 1.5.1 REFINEMENTS IN SCOPE 33 1.5.2 COVERAGE OF NEW PLAYERS 33 1.5.3 ADDITION OF SEGMENTS 33 1.5.4 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS 34 1.5.5 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS 34 1.5.6 UPDATED GEOGRAPHIC ANALYSIS 34 1.5.7 IMPACT OF AI 34 1.5.8 IMPACT OF US TARIFF 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 36 2.1.1.1 Key sources of secondary data 36 2.1.1.2 Key data from secondary sources 37 2.1.2 PRIMARY DATA 37 2.1.2.1 Key primary sources 37 2.1.2.2 Key objectives of primary research 38 2.1.2.3 Key data from primary sources 38 2.1.2.4 Key industry insights 39 2.2 MARKET SIZE ESTIMATION 40 2.2.1 REVENUE SHARE ANALYSIS 40 2.2.2 BOTTOM-UP APPROACH (SUPPLY-SIDE ANALYSIS) 43 2.2.3 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS 43 2.2.4 TOP-DOWN APPROACH 45 2.3 DATA TRIANGULATION 46 2.4 MARKET SHARE ESTIMATION 47 2.5 STUDY ASSUMPTIONS 47 2.6 RESEARCH LIMITATIONS 47 2.6.1 SCOPE-RELATED LIMITATIONS 47 2.6.2 METHODOLOGY-RELATED LIMITATIONS 47 2.7 RISK ANALYSIS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 52 4.1 DIABETES CARE DEVICES MARKET OVERVIEW 52 4.2 ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE AND COUNTRY (2024) 53 4.3 DIABETES CARE DEVICES MARKET: GEOGRAPHICAL MIX 54 4.4 DIABETES CARE DEVICES MARKET: REGIONAL MIX 54 4.5 DIABETES CARE DEVICES MARKET: DEVELOPED VS. EMERGING MARKETS 55 5 MARKET OVERVIEW 56 5.1 INTRODUCTION 56 5.2 MARKET DYNAMICS 56 5.2.1 DRIVERS 57 5.2.1.1 Surging global diabetes patient population requiring continuous care 57 5.2.1.2 Rapidly growing geriatric population 57 5.2.1.3 Increasing efforts toward public awareness and preventive healthcare 57 5.2.1.4 Rapid technological advancements in diabetes care 58 5.2.2 RESTRAINTS 58 5.2.2.1 High cost of advanced diabetes care devices 58 5.2.2.2 Limited awareness in emerging healthcare markets 58 5.2.3 OPPORTUNITIES 59 5.2.3.1 Enhanced diabetes management with advanced patient-implantable continuous glucose monitoring devices 59 5.2.4 CHALLENGES 59 5.2.4.1 Limited sensor durability with repeated and costly replacements 59 5.2.4.2 High cost and socio-economic disparities in access to diabetes care devices 60 5.3 INDUSTRY TRENDS 60 5.3.1 RISING ADOPTION OF DIGITAL HEALTH SOLUTIONS AND TELEMEDICINE INTEGRATION IN DIABETES CARE 60 5.3.2 ACCELERATING SHIFT TOWARD HOME-BASED, PATIENT-CENTRIC, AND SELF-MANAGED DIABETES CARE 60 5.4 TECHNOLOGY ANALYSIS 61 5.4.1 KEY TECHNOLOGIES 61 5.4.1.1 Implantable sensors 61 5.4.1.2 Smart automated insulin pumps 61 5.4.2 COMPLEMENTARY TECHNOLOGIES 61 5.4.2.1 Telehealth services 61 5.4.3 ADJACENT TECHNOLOGIES 62 5.4.3.1 Cutting-edge and smartphone-enabled diabetes self-management technologies 62 5.5 PRICING ANALYSIS 62 5.5.1 AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES, BY KEY PLAYER, 2022–2024 62 5.5.2 AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES, BY REGION, 2022–2024 62 5.6 ECOSYSTEM ANALYSIS 63 5.6.1 ROLE IN ECOSYSTEM 64 5.7 REIMBURSEMENT SCENARIO ANALYSIS 65 5.8 VALUE CHAIN ANALYSIS 65 5.9 PORTER’S FIVE FORCES ANALYSIS 66 5.9.1 INTENSITY OF COMPETITIVE RIVALRY 68 5.9.2 BARGAINING POWER OF SUPPLIERS 68 5.9.3 BARGAINING POWER OF BUYERS 68 5.9.4 THREAT OF SUBSTITUTES 68 5.9.5 THREAT OF NEW ENTRANTS 69 5.10 KEY STAKEHOLDERS & BUYING CRITERIA 69 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 69 5.10.2 KEY BUYING CRITERIA 70 5.11 TRADE ANALYSIS 71 5.11.1 IMPORT DATA FOR HS CODE 9027, 2020–2024 71 5.11.2 EXPORT DATA FOR HS CODE 9027, 2020–2024 71 5.12 REGULATORY ANALYSIS 72 5.12.1 REGULATORY FRAMEWORK 72 5.12.1.1 North America 72 5.12.1.1.1 US 72 5.12.1.1.2 Canada 72 5.12.1.2 Europe 72 5.12.1.3 Asia Pacific 72 5.12.1.3.1 China 72 5.12.1.3.2 Japan 72 5.12.1.3.3 India 73 5.12.1.4 Latin America 73 5.12.1.4.1 Brazil 73 5.12.1.4.2 Mexico 73 5.12.1.5 Middle East 73 5.12.1.6 Africa 74 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 74   5.13 PATENT ANALYSIS 76 5.13.1 PATENT PUBLICATION TRENDS FOR DIABETES CARE DEVICES MARKET 76 5.13.2 JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN DIABETES CARE DEVICES 77 5.13.3 LIST OF MAJOR PATENTS 78 5.14 KEY CONFERENCES & EVENTS, 2025–2026 79 5.15 ADJACENT MARKET ANALYSIS 79 5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80 5.17 UNMET NEEDS/END-USER EXPECTATIONS 80 5.17.1 UNMET NEEDS 80 5.17.2 END-USER EXPECTATIONS 81 5.18 IMPACT OF AI/GEN AI IN DIABETES CARE DEVICES MARKET 81 5.19 CASE STUDY ANALYSIS 83 5.19.1 LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSORS 83 5.19.2 ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 83 5.19.3 MEDTRONIC MINIMED INSULIN PUMP TO ENHANCE GLUCOSE CONTROL AND IMPROVE DAILY MANAGEMENT FOR PEOPLE WITH DIABETES 84 5.20 INVESTMENT & FUNDING SCENARIO 84 5.21 IMPACT OF 2025 US TARIFF ON DIABETES CARE DEVICES MARKET 85 5.21.1 INTRODUCTION 85 5.21.2 KEY TARIFF RATES 86 5.21.3 PRICE IMPACT ANALYSIS 86 5.21.4 IMPACT ON END-USE INDUSTRIES 87 6 DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE 88 6.1 INTRODUCTION 89 6.2 BLOOD GLUCOSE MONITORING SYSTEMS 90 6.2.1 SELF-MONITORING BLOOD GLUCOSE SYSTEMS 92 6.2.1.1 Need for self-monitoring in type 1 and type 2 diabetes management to propel market growth 92 6.2.2 CONTINUOUS GLUCOSE MONITORING SYSTEMS 93 6.2.2.1 Technological advancements in continuous glucose monitoring systems to track trends and enhance diabetes management 93 6.2.3 TEST STRIPS/TEST PAPERS 95 6.2.3.1 Shift toward non-invasive methods for blood glucose monitoring to restrain market growth 95 6.2.4 LANCETS/LANCING DEVICES 96 6.2.4.1 Need for infection and accidental pricking to increase popularity of safety lancets/lancing devices 96 6.3 INSULIN DELIVERY DEVICES 97 6.3.1 INSULIN PUMPS & ACCESSORIES 99 6.3.1.1 Tethered pumps 101 6.3.1.1.1 Increase in collaborations and partnerships among companies to develop integrated insulin systems 101 6.3.1.2 Tubeless insulin pumps 102 6.3.1.2.1 Use of artificial intelligence to replace traditional vial-syringe combinations with tubeless pumps 102 6.3.2 INSULIN PENS 104 6.3.2.1 Reusable insulin pens 106 6.3.2.1.1 Technology innovations and cost-effectiveness to boost market growth 106 6.3.2.2 Disposable insulin pens 107 6.3.2.2.1 Ease of use, accurate dose measurement, and built-in cartridges to propel segment growth 107 6.3.3 PEN NEEDLES 108 6.3.3.1 Reduced chances of infection and accidental pricking to augment market growth 108 6.3.4 INSULIN SYRINGES & NEEDLES 110 6.3.4.1 Safety concerns and need for affordable alternatives to limit market growth 110 6.3.5 OTHER INSULIN DELIVERY DEVICES 111 6.4 DIABETES MANAGEMENT MOBILE APPLICATIONS 114 6.4.1 INCREASING PREVALENCE OF DIABETES AND RISING ADOPTION OF BLOOD GLUCOSE TRACKING APPLICATIONS TO DRIVE MARKET 114 7 DIABETES CARE DEVICES MARKET, BY DISEASE TYPE 115 7.1 INTRODUCTION 116 7.2 TYPE 1 DIABETES 116 7.2.1 CHRONIC NATURE OF TYPE 1 DIABETES AND NEED FOR IMPROVED DIAGNOSIS TO AID MARKET GROWTH 116 7.3 TYPE 2 DIABETES 118 7.3.1 RISING BURDEN OF TYPE 2 DIABETES TO INCREASE NEED FOR SCALABLE CARE DEVICE SOLUTIONS 118 8 DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS 120 8.1 INTRODUCTION 121 8.2 SELF/HOME HEALTHCARE 122 8.2.1 INCREASING AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL PREFERENCE 122 8.3 HOSPITALS & DIABETES SPECIALTY CLINICS 124 8.3.1 RISING DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET GROWTH 124 9 DIABETES CARE DEVICES MARKET, BY REGION 126 9.1 INTRODUCTION 127 9.2 NORTH AMERICA 128 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 128 9.2.2 US 132 9.2.2.1 US to dominate North American diabetes care devices market during forecast period 132 9.2.3 CANADA 135 9.2.3.1 High prevalence of diabetes and supportive government disease management initiatives to spur market growth 135 9.3 EUROPE 138 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 138 9.3.2 GERMANY 142 9.3.2.1 Advanced healthcare infrastructure to drive adoption of innovative diabetes care devices 142 9.3.3 UK 145 9.3.3.1 Increased government support and improved research funding to propel market growth 145 9.3.4 FRANCE 148 9.3.4.1 Substantial national spending on diabetes management and robust healthcare infrastructure to aid market growth 148 9.3.5 ITALY 151 9.3.5.1 High diabetes-related mortality and increased public investment to augment market growth 151 9.3.6 SPAIN 153 9.3.6.1 Minimal co-payments and full reimbursement to drive market 153 9.3.7 REST OF EUROPE 156 9.4 ASIA PACIFIC 159 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 159 9.4.2 CHINA 163 9.4.2.1 Huge diabetic population and high government healthcare spending to spur market growth 163 9.4.3 JAPAN 166 9.4.3.1 Increased geriatric population and supportive healthcare policies to support market growth 166 9.4.4 INDIA 169 9.4.4.1 Rise in diabetes cases and affordable local manufacturing to fuel diabetes care devices demand 169 9.4.5 AUSTRALIA 172 9.4.5.1 Comprehensive government-backed initiatives and subsidies to support market growth 172 9.4.6 SOUTH KOREA 175 9.4.6.1 Rise in diabetes cases and strong government healthcare support to boost market growth 175 9.4.7 REST OF ASIA PACIFIC 178 9.5 LATIN AMERICA 181 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 181 9.5.2 BRAZIL 185 9.5.2.1 Increasing adoption of advanced diabetes monitoring and management solutions to aid market growth 185   9.5.3 MEXICO 188 9.5.3.1 Supportive regulatory frameworks and high burden of diabetes to propel market growth 188 9.5.4 REST OF LATIN AMERICA 191 9.6 MIDDLE EAST & AFRICA 194 9.6.1 INCREASING AWARENESS OF EARLY DIAGNOSIS AND GLYCEMIC CONTROL FOR DIABETES MANAGEMENT TO FAVOR MARKET GROWTH 194 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 194 9.7 GCC COUNTRIES 197 9.7.1 RISE IN DIABETES PREVALENCE AND HIGH PER CAPITA HEALTHCARE EXPENDITURE TO DRIVE MARKET 197 9.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 198 10 COMPETITIVE LANDSCAPE 201 10.1 INTRODUCTION 201 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 201 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIABETES CARE DEVICES MARKET 202 10.3 REVENUE ANALYSIS, 2020–2024 203 10.4 MARKET SHARE ANALYSIS, 2024 203 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 206 10.5.1 STARS 206 10.5.2 EMERGING LEADERS 206 10.5.3 PERVASIVE PLAYERS 206 10.5.4 PARTICIPANTS 206 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 208 10.5.5.1 Company footprint 208 10.5.5.2 Region footprint 209 10.5.5.3 Product type footprint 210 10.5.5.4 Patient care settings footprint 211 10.5.5.5 Disease type footprint 212 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 213 10.6.1 PROGRESSIVE COMPANIES 213 10.6.2 RESPONSIVE COMPANIES 213 10.6.3 DYNAMIC COMPANIES 213 10.6.4 STARTING BLOCKS 213 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 215 10.6.5.1 Detailed list of key startups/SMEs 215 10.6.5.2 Competitive benchmarking of key startups/SMEs 215 10.7 COMPANY VALUATION & FINANCIAL METRICS 216 10.7.1 FINANCIAL METRICS 216 10.7.2 COMPANY VALUATION 216   10.8 BRAND/PRODUCT COMPARISON 217 10.9 R&D EXPENDITURE OF KEY PLAYERS 218 10.10 COMPETITIVE SCENARIO 218 10.10.1 PRODUCT LAUNCHES AND APPROVALS 218 10.10.2 DEALS 219 10.10.3 EXPANSIONS 220 10.10.4 OTHER DEVELOPMENTS 220 11 COMPANY PROFILES 221 11.1 KEY PLAYERS 221 11.1.1 F. HOFFMAN-LA ROCHE LTD. 221 11.1.1.1 Business overview 221 11.1.1.2 Products/Solutions offered 222 11.1.1.3 Recent developments 223 11.1.1.3.1 Product launches & approvals 223 11.1.1.3.2 Deals 224 11.1.1.3.3 Expansions 224 11.1.1.4 MnM view 225 11.1.1.4.1 Right to win 225 11.1.1.4.2 Strategic choices 225 11.1.1.4.3 Weaknesses & competitive threats 225 11.1.2 ABBOTT 226 11.1.2.1 Business overview 226 11.1.2.2 Products/Solutions offered 228 11.1.2.3 Recent developments 229 11.1.2.3.1 Product launches & approvals 229 11.1.2.3.2 Deals 230 11.1.2.3.3 Expansions 231 11.1.2.3.4 Other developments 231 11.1.2.4 MnM view 231 11.1.2.4.1 Right to win 231 11.1.2.4.2 Strategic choices 232 11.1.2.4.3 Weaknesses & competitive threats 232 11.1.3 DEXCOM, INC. 233 11.1.3.1 Business overview 233 11.1.3.2 Products/Solutions offered 234 11.1.3.3 Recent developments 235 11.1.3.3.1 Product launches & approvals 235 11.1.3.3.2 Deals 236 11.1.3.3.3 Expansions 236   11.1.3.4 MnM view 237 11.1.3.4.1 Right to win 237 11.1.3.4.2 Strategic choices 237 11.1.3.4.3 Weaknesses & competitive threats 237 11.1.4 MEDTRONIC 238 11.1.4.1 Business overview 238 11.1.4.2 Products/Solutions offered 239 11.1.4.3 Recent developments 240 11.1.4.3.1 Product launches & approvals 240 11.1.4.3.2 Deals 241 11.1.4.3.3 Expansions 242 11.1.4.3.4 Other developments 242 11.1.4.4 MnM view 242 11.1.4.4.1 Right to win 242 11.1.4.4.2 Strategic choices 243 11.1.4.4.3 Weaknesses & competitive threats 243 11.1.5 B. BRAUN SE 244 11.1.5.1 Business overview 244 11.1.5.2 Products/Solutions offered 245 11.1.5.3 MnM view 246 11.1.5.3.1 Right to win 246 11.1.5.3.2 Strategic choices 246 11.1.5.3.3 Weaknesses & competitive threats 246 11.1.6 EMBECTA CORP. 247 11.1.6.1 Business overview 247 11.1.6.2 Products/Solutions offered 249 11.1.6.3 Recent developments 249 11.1.6.3.1 Product approvals 249 11.1.6.3.2 Deals 249 11.1.6.3.3 Expansions 250 11.1.6.3.4 Other developments 250 11.1.7 NIPRO 251 11.1.7.1 Business overview 251 11.1.7.2 Products/Solutions offered 252 11.1.7.3 Recent developments 253 11.1.7.3.1 Expansions 253 11.1.8 SENSEONICS 254 11.1.8.1 Business overview 254 11.1.8.2 Products/Solutions offered 255 11.1.8.3 Recent developments 256 11.1.8.3.1 Product launches & approvals 256 11.1.8.3.2 Deals 256 11.1.8.3.3 Other developments 257 11.1.9 YPSOMED 258 11.1.9.1 Business overview 258 11.1.9.2 Products/Solutions offered 259 11.1.9.3 Recent developments 260 11.1.9.3.1 Product launches & approvals 260 11.1.9.3.2 Deals 261 11.1.9.3.3 Expansions 262 11.1.9.3.4 Other developments 263 11.1.10 I-SENS, INC. 264 11.1.10.1 Business overview 264 11.1.10.2 Products/Solutions offered 265 11.1.10.3 Recent developments 266 11.1.10.3.1 Product approvals 266 11.1.10.3.2 Deals 266 11.1.11 TANDEM DIABETES CARE, INC. 267 11.1.11.1 Business overview 267 11.1.11.2 Products/Solutions offered 268 11.1.11.3 Recent developments 269 11.1.11.3.1 Product launches & approvals 269 11.1.11.3.2 Deals 270 11.1.12 INSULET CORPORATION 272 11.1.12.1 Business overview 272 11.1.12.2 Products/Solutions offered 273 11.1.12.3 Recent developments 274 11.1.12.3.1 Product launches & approvals 274 11.1.12.3.2 Deals 276 11.1.12.3.3 Expansions 276 11.1.12.3.4 Other developments 277 11.1.13 ACON LABORATORIES, INC. 278 11.1.13.1 Business overview 278 11.1.13.2 Products/Solutions offered 278 11.1.14 ARKRAY, INC. 280 11.1.14.1 Business overview 280 11.1.14.2 Products/Solutions offered 280 11.1.14.3 Recent developments 281 11.1.14.3.1 Product launches 281 11.1.15 TERUMO CORPORATION 282 11.1.15.1 Business overview 282 11.1.15.2 Products/Solutions offered 283 11.1.15.3 Recent developments 284 11.1.15.3.1 Product launches 284 11.1.15.3.2 Deals 284 11.1.15.3.3 Expansions 285 11.1.15.3.4 Other developments 285 11.2 OTHER PLAYERS 286 11.2.1 SINOCARE 286 11.2.2 AGAMATRIX 288 11.2.3 LIFESCAN IP HOLDINGS, LLC 289 11.2.4 SD BIOSENSOR, INC. 290 11.2.5 DEBIOTECH S.A. 291 11.2.6 SUNGSHIM MEDICAL CO., LTD. 292 11.2.7 SOOIL DEVELOPMENTS CO., LTD. 293 11.2.8 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD. 294 11.2.9 MICROGENE DIAGNOSTIC SYSTEMS (P) LTD. 295 11.2.10 ROSSMAX INTERNATIONAL LTD. 296 12 APPENDIX 297 12.1 DISCUSSION GUIDE 297 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 300 12.3 CUSTOMIZATION OPTIONS 302 12.4 RELATED REPORTS 302 12.5 AUTHOR DETAILS 303
圖表清單 List of Tables & Figures
TABLE 1 DIABETES CARE DEVICES MARKET: INCLUSIONS & EXCLUSIONS 31 TABLE 2 STANDARD CURRENCY CONVERSION RATES 32 TABLE 3 STUDY ASSUMPTIONS IN DIABETES CARE DEVICES MARKET 47 TABLE 4 RISK ANALYSIS IN DIABETES CARE DEVICES MARKET 48 TABLE 5 AVERAGE SELLING PRICE TREND OF DIABETES CARE DEVICES, BY KEY PLAYER, 2022–2024 (USD) 62 TABLE 6 AVERAGE SELLING PRICE TREND OF DIABETES CARE, BY REGION, 2022–2024 (USD) 63 TABLE 7 DIABETES CARE DEVICES MARKET: ROLE IN ECOSYSTEM 64 TABLE 8 DIABETES CARE DEVICES MARKET: PORTER’S FIVE FORCES 67 TABLE 9 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 69 TABLE 10 KEY BUYING CRITERIA FOR MAJOR END USERS 70 TABLE 11 IMPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND) 71 TABLE 12 EXPORT DATA FOR HS CODE 9027, BY COUNTRY, 2020–2024 (USD THOUSAND) 71 TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 18 LIST OF MAJOR PATENTS IN DIABETES CARE DEVICES MARKET, 2022–2024 78 TABLE 19 DIABETES CARE DEVICES MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 79 TABLE 20 UNMET NEEDS IN DIABETES CARE DEVICES MARKET 80 TABLE 21 END-USER EXPECTATIONS IN DIABETES CARE DEVICES MARKET 81 TABLE 22 IMPACT OF AI/GEN AI IN DIABETES CARE DEVICES MARKET 82 TABLE 23 CASE STUDY 1: LONG-TERM GLUCOSE MONITORING FOR SENSITIVE SKIN PATIENTS USING SENSEONICS’ EVERSENSE E3 IMPLANTABLE SENSORS 83 TABLE 24 CASE STUDY 2: ENHANCING PATIENT ADHERENCE AND GLYCEMIC CONTROL USING ABBOTT’S FREESTYLE LIBRE 2 CGM 83 TABLE 25 CASE STUDY 3: MEDTRONIC MINIMED INSULIN PUMP TO ENHANCE GLUCOSE CONTROL AND IMPROVE DAILY MANAGEMENT FOR PEOPLE WITH DIABETES 84 TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES 86 TABLE 27 DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 89 TABLE 28 DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 90 TABLE 29 DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 91 TABLE 30 DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2023–2030 (USD MILLION) 91 TABLE 31 SELF-MONITORING BLOOD GLUCOSE SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 93 TABLE 32 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 94 TABLE 33 TEST STRIPS/TEST PAPERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 96 TABLE 34 LANCETS/LANCING DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 97 TABLE 35 DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 98 TABLE 36 DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY COUNTRY, 2023–2030 (USD MILLION) 98 TABLE 37 INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 99 TABLE 38 INSULIN PUMPS & ACCESSORIES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 99 TABLE 39 INSULIN PUMPS & ACCESSORIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 40 TETHERED INSULIN PUMPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 41 TUBELESS INSULIN PUMPS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 42 INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 104 TABLE 43 INSULIN PENS MARKET, COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 44 REUSABLE INSULIN PENS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 45 DISPOSABLE INSULIN PENS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 46 PEN NEEDLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 47 INSULIN SYRINGES & NEEDLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 48 OTHER INSULIN DELIVERY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 49 DIABETES CARE DEVICES MARKET FOR DIABETES MANAGEMENT MOBILE APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 50 DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 116 TABLE 51 TYPE 1 DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 52 TYPE 2 DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 53 DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 121 TABLE 54 DIABETES CARE DEVICES MARKET FOR SELF/HOME HEALTHCARE, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 55 DIABETES CARE DEVICES MARKET FOR HOSPITAL & DIABETES SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 56 DIABETES CARE DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 57 NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 58 NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 130 TABLE 59 NORTH AMERICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 130 TABLE 60 NORTH AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 61 NORTH AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 62 NORTH AMERICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 131 TABLE 63 NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 132 TABLE 64 NORTH AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 132 TABLE 65 US: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 133 TABLE 66 US: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 133 TABLE 67 US: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 68 US: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 69 US: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 134 TABLE 70 US: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 135 TABLE 71 US: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 135 TABLE 72 CANADA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 136 TABLE 73 CANADA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 136 TABLE 74 CANADA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 75 CANADA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 76 CANADA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 137 TABLE 77 CANADA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 138 TABLE 78 CANADA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 138 TABLE 79 EUROPE: DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 80 EUROPE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 139 TABLE 81 EUROPE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 82 EUROPE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 83 EUROPE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 84 EUROPE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 85 EUROPE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 141 TABLE 86 EUROPE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 141 TABLE 87 GERMANY: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 142 TABLE 88 GERMANY: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 89 GERMANY: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 90 GERMANY: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 143 TABLE 91 GERMANY: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 144 TABLE 92 GERMANY: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 144 TABLE 93 GERMANY: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 144 TABLE 94 UK: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 145 TABLE 95 UK: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 96 UK: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 97 UK: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 98 UK: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147 TABLE 99 UK: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 147 TABLE 100 UK: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 147 TABLE 101 FRANCE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 148 TABLE 102 FRANCE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 103 FRANCE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 104 FRANCE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 105 FRANCE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 150 TABLE 106 FRANCE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 150 TABLE 107 FRANCE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 150 TABLE 108 ITALY: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 151 TABLE 109 ITALY: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 110 ITALY: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 111 ITALY: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 112 ITALY: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 153 TABLE 113 ITALY: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 153 TABLE 114 ITALY: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 153 TABLE 115 SPAIN: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 154 TABLE 116 SPAIN: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 117 SPAIN: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 118 SPAIN: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 119 SPAIN: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 155 TABLE 120 SPAIN: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 156 TABLE 121 SPAIN: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 156 TABLE 122 REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 157 TABLE 123 REST OF EUROPE: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 124 REST OF EUROPE: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 125 REST OF EUROPE: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 126 REST OF EUROPE: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 127 REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 159 TABLE 128 REST OF EUROPE: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 159 TABLE 129 ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 130 ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 161 TABLE 131 ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 132 ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 133 ASIA PACIFIC: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 134 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 162 TABLE 135 ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 163 TABLE 136 ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 163 TABLE 137 CHINA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 164 TABLE 138 CHINA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 164 TABLE 139 CHINA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 140 CHINA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 141 CHINA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 142 CHINA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 166 TABLE 143 CHINA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 166 TABLE 144 JAPAN: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 167 TABLE 145 JAPAN: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 167 TABLE 146 JAPAN: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 147 JAPAN: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 148 JAPAN: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 168 TABLE 149 JAPAN: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 169 TABLE 150 JAPAN: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 169 TABLE 151 INDIA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 170 TABLE 152 INDIA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 153 INDIA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 154 INDIA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 155 INDIA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 156 INDIA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 172 TABLE 157 INDIA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 172 TABLE 158 AUSTRALIA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 173 TABLE 159 AUSTRALIA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 173 TABLE 160 AUSTRALIA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 161 AUSTRALIA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 162 AUSTRALIA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 163 AUSTRALIA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 175 TABLE 164 AUSTRALIA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 175 TABLE 165 SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 176 TABLE 166 SOUTH KOREA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 167 SOUTH KOREA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 168 SOUTH KOREA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 169 SOUTH KOREA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 170 SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 178 TABLE 171 SOUTH KOREA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 178 TABLE 172 REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 179 TABLE 173 REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 174 REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 175 REST OF ASIA PACIFIC: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 176 REST OF ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 177 REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 181 TABLE 178 REST OF ASIA PACIFIC: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 181 TABLE 179 LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 180 LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 182 TABLE 181 LATIN AMERICA: DIABETES CARE DEVICES MARTKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 182 LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 183 LATIN AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 183 TABLE 184 LATIN AMERICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 185 LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 184 TABLE 186 LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 184 TABLE 187 BRAZIL: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 185 TABLE 188 BRAZIL: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 189 BRAZIL: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 190 BRAZIL: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 191 BRAZIL: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 192 BRAZIL: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 187 TABLE 193 BRAZIL: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 187 TABLE 194 MEXICO: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 188 TABLE 195 MEXICO: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 196 MEXICO: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 197 MEXICO: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 198 MEXICO: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 199 MEXICO: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 190 TABLE 200 MEXICO: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 190 TABLE 201 REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 191 TABLE 202 REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 203 REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 204 REST OF LATIN AMERICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 205 REST OF LATIN AMERICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 206 REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 193 TABLE 207 REST OF LATIN AMERICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 193 TABLE 208 MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 195 TABLE 209 MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 210 MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 211 MIDDLE EAST & AFRICA: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 212 MIDDLE EAST & AFRICA: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 213 MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 197 TABLE 214 MIDDLE EAST & AFRICA: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 197 TABLE 215 GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION) 198 TABLE 216 GCC COUNTRIES: DIABETES CARE DEVICES MARKET FOR BLOOD GLUCOSE MONITORING SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 217 GCC COUNTRIES: DIABETES CARE DEVICES MARKET FOR INSULIN DELIVERY DEVICES, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 218 GCC COUNTRIES: INSULIN PUMPS & ACCESSORIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 219 GCC COUNTRIES: INSULIN PENS MARKET, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 220 GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2023–2030 (USD MILLION) 200 TABLE 221 GCC COUNTRIES: DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2023–2030 (USD MILLION) 200 TABLE 222 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIABETES CARE DEVICES MARKET, JANUARY 2022–AUGUST 2025 202 TABLE 223 DIABETES CARE DEVICES MARKET: DEGREE OF COMPETITION 204 TABLE 224 DIABETES CARE DEVICES MARKET: REGION FOOTPRINT 209 TABLE 225 DIABETES CARE DEVICES MARKET: PRODUCT TYPE FOOTPRINT 210 TABLE 226 DIABETES CARE DEVICES MARKET: PATIENT CARE SETTINGS FOOTPRINT 211 TABLE 227 DIABETES CARE DEVICES MARKET: DISEASE TYPE FOOTPRINT 212 TABLE 228 DIABETES CARE DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 215 TABLE 229 DIABETES CARE DEVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT TYPE AND REGION 215 TABLE 230 DIABETES CARE DEVICES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– JUNE 2025 218 TABLE 231 DIABETES CARE DEVICES MARKET: DEALS, JANUARY 2022– JUNE 2025 219 TABLE 232 DIABETES CARE DEVICES MARKET: EXPANSIONS, JANUARY 2022– JUNE 2025 220 TABLE 233 DIABETES CARE DEVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2022– JUNE 2025 220 TABLE 234 F. HOFFMAN-LA ROCHE LTD.: COMPANY OVERVIEW 221 TABLE 235 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED 222 TABLE 236 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 223 TABLE 237 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–AUGUST 2025 224 TABLE 238 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–AUGUST 2025 224 TABLE 239 ABBOTT: COMPANY OVERVIEW 226 TABLE 240 ABBOTT: PRODUCTS/SOLUTIONS OFFERED 228 TABLE 241 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 229 TABLE 242 ABBOTT: DEALS, JANUARY 2022–AUGUST 2025 230 TABLE 243 ABBOTT: EXPANSIONS, JANUARY 2022–AUGUST 2025 231 TABLE 244 ABBOTT: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 231 TABLE 245 DEXCOM, INC.: COMPANY OVERVIEW 233 TABLE 246 DEXCOM, INC.: PRODUCTS/SOLUTIONS OFFERED 234 TABLE 247 DEXCOM, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 235 TABLE 248 DEXCOM, INC.: DEALS, JANUARY 2022–AUGUST 2025 236 TABLE 249 DEXCOM, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025 236 TABLE 250 MEDTRONIC: COMPANY OVERVIEW 238 TABLE 251 MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED 239 TABLE 252 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 240 TABLE 253 MEDTRONIC: DEALS, JANUARY 2022–AUGUST 2025 241 TABLE 254 MEDTRONIC: EXPANSIONS, JANUARY 2022–AUGUST 2025 242 TABLE 255 MEDTRONIC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 242 TABLE 256 B. BRAUN SE: COMPANY OVERVIEW 244 TABLE 257 B. BRAUN SE: PRODUCTS/SOLUTIONS OFFERED 245 TABLE 258 EMBECTA CORP.: COMPANY OVERVIEW 247 TABLE 259 EMBECTA CORP.: PRODUCTS/SOLUTIONS OFFERED 249 TABLE 260 EMBECTA CORP.: PRODUCTS APPROVALS, JANUARY 2022–AUGUST 2025 249 TABLE 261 EMBECTA CORP.: DEALS, JANUARY 2022–AUGUST 2025 249 TABLE 262 EMBECTA CORP.: EXPANSIONS, JANUARY 2022–AUGUST 2025 250 TABLE 263 EMBECTA CORP.: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 250 TABLE 264 NIPRO: COMPANY OVERVIEW 251 TABLE 265 NIPRO: PRODUCTS/SOLUTIONS OFFERED 252 TABLE 266 NIPRO: EXPANSIONS, JANUARY 2022–AUGUST 2025 253 TABLE 267 SENSEONICS: COMPANY OVERVIEW 254 TABLE 268 SENSEONICS: PRODUCTS/SOLUTIONS OFFERED 255 TABLE 269 SENSEONICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 256 TABLE 270 SENSEONICS: DEALS, JANUARY 2022–AUGUST 2025 256 TABLE 271 SENSEONICS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 257 TABLE 272 YPSOMED: COMPANY OVERVIEW 258 TABLE 273 YPSOMED: PRODUCTS/SOLUTIONS OFFERED 259 TABLE 274 YPSOMED: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 260 TABLE 275 YPSOMED: DEALS, JANUARY 2022–AUGUST 2025 261 TABLE 276 YPSOMED: EXPANSIONS, JANUARY 2022–AUGUST 2025 262 TABLE 277 YPSOMED: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 263 TABLE 278 I-SENS, INC.: COMPANY OVERVIEW 264 TABLE 279 I-SENS, INC.: PRODUCTS/SOLUTIONS OFFERED 265 TABLE 280 I-SENS, INC.: PRODUCTS APPROVALS, JANUARY 2022–AUGUST 2025 266 TABLE 281 I-SENS, INC.: DEALS, JANUARY 2022–AUGUST 2025 266 TABLE 282 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 267 TABLE 283 TANDEM DIABETES CARE, INC.: PRODUCTS/SOLUTIONS OFFERED 268 TABLE 284 TANDEM DIABETES CARE, INC.: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 269 TABLE 285 TANDEM DIABETES CARE, INC.: DEALS, JANUARY 2022–AUGUST 2025 270 TABLE 286 INSULET CORPORATION: COMPANY OVERVIEW 272 TABLE 287 INSULET CORPORATION: PRODUCTS/SOLUTIONS OFFERED 273 TABLE 288 INSULET CORPORATION: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025 274 TABLE 289 INSULET CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 276 TABLE 290 INSULET CORPORATION: EXPANSIONS, JANUARY 2022–AUGUST 2025 276 TABLE 291 INSULET CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 277 TABLE 292 ACON LABORATORIES, INC.: COMPANY OVERVIEW 278 TABLE 293 ACON LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED 278 TABLE 294 ARKRAY, INC.: COMPANY OVERVIEW 280 TABLE 295 ARKRAY, INC.: PRODUCTS/SOLUTIONS OFFERED 280 TABLE 296 ARKRAY, INC.: PRODUCTS LAUNCHES, JANUARY 2022–AUGUST 2025 281 TABLE 297 TERUMO CORPORATION: COMPANY OVERVIEW 282 TABLE 298 TERUMO CORPORATION: PRODUCTS/SOLUTIONS OFFERED 283 TABLE 299 TERUMO CORPORATION: PRODUCTS LAUNCHES, JANUARY 2022–AUGUST 2025 284 TABLE 300 TERUMO CORPORATION: DEALS, JANUARY 2022–AUGUST 2025 284 TABLE 301 TERUMO CORPORATION: EXPANSIONS, JANUARY 2022–AUGUST 2025 285 TABLE 302 TERUMO CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 285 TABLE 303 SINOCARE: COMPANY OVERVIEW 286 TABLE 304 AGAMATRIX: COMPANY OVERVIEW 288 TABLE 305 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW 289 TABLE 306 SD BIOSENSOR, INC.: COMPANY OVERVIEW 290 TABLE 307 DEBIOTECH S.A.: COMPANY OVERVIEW 291 TABLE 308 SUNGSHIM MEDICAL CO., LTD.: COMPANY OVERVIEW 292 TABLE 309 SOOIL DEVELOPMENTS CO., LTD.: COMPANY OVERVIEW 293 TABLE 310 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD.: COMPANY OVERVIEW 294 TABLE 311 MICROGENE DIAGNOSTIC SYSTEMS (P) LTD.: COMPANY OVERVIEW 295 TABLE 312 ROSSMAX INTERNATIONAL LTD.: COMPANY OVERVIEW 296 FIGURE 1 DIABETES CARE DEVICES MARKET SEGMENTATION & REGIONAL SCOPE 30 FIGURE 2 DIABETES CARE DEVICES MARKET: YEARS CONSIDERED 32 FIGURE 3 DIABETES CARE DEVICES MARKET: RESEARCH DESIGN 35 FIGURE 4 DIABETES CARE DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES 37 FIGURE 5 DIABETES CARE DEVICES MARKET: KEY PRIMARY SOURCES (SUPPLY AND DEMAND SIDES) 37 FIGURE 6 DIABETES CARE DEVICES MARKET: KEY DATA FROM PRIMARY SOURCES 38 FIGURE 7 DIABETES CARE DEVICES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 39 FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 39 FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 40 FIGURE 10 DIABETES CARE DEVICES MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2024) 41 FIGURE 11 DIABETES CARE DEVICES MARKET: REVENUE SHARE ANALYSIS FOR ABBOTT (US) (2024) 41 FIGURE 12 SUPPLY-SIDE ANALYSIS OF DIABETES CARE DEVICES MARKET (2024) 42 FIGURE 13 DIABETES CARE DEVICES MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 42 FIGURE 14 DIABETES CARE DEVICES MARKET: BOTTOM-UP APPROACH 43 FIGURE 15 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS IN DIABETES CARE DEVICES MARKET (2025–2030) 44 FIGURE 16 DIABETES CARE DEVICES MARKET: TOP-DOWN APPROACH 45 FIGURE 17 DIABETES CARE DEVICES MARKET: DATA TRIANGULATION 46 FIGURE 18 DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD MILLION) 49 FIGURE 19 DIABETES CARE DEVICES MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION) 50 FIGURE 20 DIABETES CARE DEVICES MARKET, BY PATIENT CARE SETTINGS, 2025 VS. 2030 (USD MILLION) 50 FIGURE 21 REGIONAL SNAPSHOT OF DIABETES CARE DEVICES MARKET 51 FIGURE 22 TECHNOLOGICAL ADVANCEMENTS IN DIABETES CARE DEVICES TO DRIVE MARKET 52 FIGURE 23 CHINA AND BLOOD GLUCOSE MONITORING SYSTEMS COMMNADED LARGEST ASIA PACIFIC MARKET SHARE IN 2024 53 FIGURE 24 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 54 FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 54 FIGURE 26 EMERGING MARKETS TO ACCOUNT FOR HIGHER GROWTH RATES DURING STUDY PERIOD 55 FIGURE 27 DIABETES CARE DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 28 DIABETES CARE DEVICES MARKET: ECOSYSTEM ANALYSIS 64 FIGURE 29 DIABETES CARE DEVICES MARKET: VALUE CHAIN ANALYSIS 66 FIGURE 30 DIABETES CARE DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 67 FIGURE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 69 FIGURE 32 KEY BUYING CRITERIA FOR MAJOR END USERS 70 FIGURE 33 TOP PATENT APPLICANTS/OWNERS (COMPANIES/INSTITUTES) FOR DIABETES CARE DEVICES MARKET (JANUARY 2014–DECEMBER 2024) 77 FIGURE 34 TOP PATENT APPLICANT COUNTRIES FOR PATENTS ON DIABETES CARE DEVICES (JANUARY 2014–DECEMBER 2024) 78 FIGURE 35 ADJACENT MARKETS TO DIABETES CARE DEVICES MARKET 79 FIGURE 36 DIABETES CARE DEVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80 FIGURE 37 IMPACT OF AI/GEN AI ON DIABETES CARE DEVICES MARKET 82 FIGURE 38 FUNDING AND NUMBER OF DEALS IN DIABETES CARE DEVICES MARKET, 2019–2023 (USD MILLION) 84 FIGURE 39 GEOGRAPHIC SNAPSHOT OF DIABETES CARE DEVICES MARKET 127 FIGURE 40 NORTH AMERICA: DIABETES CARE DEVICES MARKET SNAPSHOT 129 FIGURE 41 ASIA PACIFIC: DIABETES CARE DEVICES MARKET SNAPSHOT 160 FIGURE 42 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN DIABETES CARE DEVICES MARKET (2020–2024) 203 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DIABETES CARE DEVICES MARKET (2024) 204 FIGURE 44 DIABETES CARE DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 207 FIGURE 45 DIABETES CARE DEVICES MARKET: COMPANY FOOTPRINT 208 FIGURE 46 DIABETES CARE DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 214 FIGURE 47 EV/EBITDA OF KEY VENDORS 216 FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 216 FIGURE 49 DIABETES CARE DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 217 FIGURE 50 R&D EXPENDITURE OF KEY PLAYERS IN DIABETES CARE DEVICES MARKET (2022–2024) 218 FIGURE 51 F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT 222 FIGURE 52 ABBOTT: COMPANY SNAPSHOT 227 FIGURE 53 DEXCOM, INC.: COMPANY SNAPSHOT 234 FIGURE 54 MEDTRONIC: COMPANY SNAPSHOT 239 FIGURE 55 B. BRAUN SE: COMPANY SNAPSHOT 244 FIGURE 56 EMBECTA CORP.: COMPANY SNAPSHOT 248 FIGURE 57 NIPRO: COMPANY SNAPSHOT 252 FIGURE 58 SENSEONICS: COMPANY SNAPSHOT 255 FIGURE 59 YPSOMED: COMPANY SNAPSHOT 259 FIGURE 60 I-SENS, INC.: COMPANY SNAPSHOT 264 FIGURE 61 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT 268 FIGURE 62 INSULET CORPORATION: COMPANY SNAPSHOT 273 FIGURE 63 TERUMO CORPORATION: COMPANY SNAPSHOT 283

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們